IN2012DN02073A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02073A
IN2012DN02073A IN2073DEN2012A IN2012DN02073A IN 2012DN02073 A IN2012DN02073 A IN 2012DN02073A IN 2073DEN2012 A IN2073DEN2012 A IN 2073DEN2012A IN 2012DN02073 A IN2012DN02073 A IN 2012DN02073A
Authority
IN
India
Prior art keywords
hcg
including recombinant
preparations including
preparations
recombinant hcg
Prior art date
Application number
Other languages
English (en)
Inventor
Ian Cottingham
Daniel Plaksin
Richard Boyd White
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of IN2012DN02073A publication Critical patent/IN2012DN02073A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/24Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/59Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/1048Glycosyltransferases (2.4)
    • C12N9/1081Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/005Glycopeptides, glycoproteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y204/00Glycosyltransferases (2.4)
    • C12Y204/99Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IN2073DEN2012 2009-10-05 2010-10-04 IN2012DN02073A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09252360 2009-10-05
PCT/GB2010/001854 WO2011042688A1 (en) 2009-10-05 2010-10-04 Pharmaceutical preparation comprising recombinant hcg

Publications (1)

Publication Number Publication Date
IN2012DN02073A true IN2012DN02073A (es) 2015-08-21

Family

ID=41471027

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2073DEN2012 IN2012DN02073A (es) 2009-10-05 2010-10-04

Country Status (25)

Country Link
US (5) US8975226B2 (es)
EP (2) EP3611185A1 (es)
JP (6) JP6176924B2 (es)
KR (7) KR20170133531A (es)
CN (1) CN107050434B (es)
AR (2) AR079876A1 (es)
AU (1) AU2010304922B2 (es)
BR (1) BR112012007990A2 (es)
CA (1) CA2776790A1 (es)
DK (1) DK2486051T3 (es)
ES (1) ES2798258T3 (es)
HR (1) HRP20200941T1 (es)
HU (1) HUE050793T2 (es)
IL (3) IL218548A (es)
IN (1) IN2012DN02073A (es)
JO (1) JOP20200039A1 (es)
LT (1) LT2486051T (es)
MX (1) MX2012003951A (es)
PL (1) PL2486051T3 (es)
PT (1) PT2486051T (es)
RS (1) RS60413B1 (es)
RU (2) RU2724528C2 (es)
SI (1) SI2486051T1 (es)
TW (2) TWI604850B (es)
WO (1) WO2011042688A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI604850B (zh) 2009-10-05 2017-11-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2691119B1 (en) * 2011-03-31 2018-08-01 Ferring B.V. Pharmaceutical preparation
WO2012168680A1 (en) * 2011-06-06 2012-12-13 Ferring B.V. Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) * 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
WO2013093760A2 (en) * 2011-12-19 2013-06-27 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
EP2930241B1 (en) 2012-12-10 2019-06-26 Seikagaku Corporation Novel recombinant factor c and method for producing same, and method for measuring endotoxin
WO2016102436A1 (en) * 2014-12-22 2016-06-30 F. Hoffmann-La Roche Ag Cmp-dependent sialidase activity
CN114107315A (zh) * 2015-04-24 2022-03-01 辉凌公司 产生促性腺激素的方法
ES2770860T3 (es) 2015-06-26 2020-07-03 Ferring Bv Métodos de purificación y/o inactivación viral
JP2021522268A (ja) * 2018-04-30 2021-08-30 フェリング ベスローテン フェンノートシャップ 制御された卵巣刺激のための組成物
CA3168469A1 (en) * 2020-02-05 2021-08-12 Novartis Ag Cho cell expressing il-15 heterodimers

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4840896A (en) * 1983-11-02 1989-06-20 Integrated Genetics, Inc. Heteropolymeric protein
DK49987A (da) * 1987-01-30 1988-07-31 Nordisk Gentofte Fremgangsmaade til behandling af infertilitet og middel til anvendelse ved fremgangsmaaden
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
PT814841E (pt) * 1995-03-21 2002-03-28 Applied Research Systems Formulacoes liquidas de hcg
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
PT996629E (pt) 1997-06-25 2006-12-29 Applied Research Systems Análogos de hormonas glicoproteicas reticulados com ligações dissulfito, sua preparação e utilização
US6500627B1 (en) 1998-02-03 2002-12-31 The Trustees Of Columbia University In The City Of New York Methods for predicting pregnancy outcome in a subject by HCG assay
WO2003050286A1 (en) * 2001-10-29 2003-06-19 Crucell Holland B.V. Methods and means for producing proteins with predetermined post-translational modifications
WO2000067778A1 (en) 1999-05-07 2000-11-16 Applied Research Systems Ars Holding N.V. Gonadotrophins
CA2399020A1 (en) 2000-02-22 2001-08-30 Applied Research Systems Ars Holding N.V. Process of purification of hcg and recombinant hcg purified by that method
RS21004A (en) 2001-09-12 2006-12-15 Aplied Research Systems Ars Holding N.V. Use of hcg in controlled ovarian hyperstimulation
WO2004099231A2 (en) * 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
EA007030B1 (ru) 2001-10-22 2006-06-30 Апплайд Резеч Системз Арс Холдинг Н.В. Гонадотропины для фолликулогенеза
BR0213402A (pt) 2001-10-29 2004-10-13 Crucell Holland Bv Métodos para identificar uma célula de mamìfero capaz de produzir uma molécula proteinácea, para selecionar uma célula de mamìfero capaz de produzir uma molécula proteinácea, para se obter uma célula de mamìfero a partir de uma população heterogênea de células, e para produzir uma molécula proteinácea, composição farmaceuticamente aceitável, eritropoietina recombinantemente produzida, usos de uma célula de mamìfero, da eritropoietina recombinantemente produzida, e de uma composição de moléculas semelhantes à eritropoietina, preparação farmacêutica, método para o tratamento preventivo e/ou terapêutico de um distúrbio, composição de moléculas semelhates à eritropoietina, métodos para produzir, em uma célula de mamìfero, moléculas proteináceas, para produzir uma fração enriquecida em uma molécula proteinácea, e para fracionar uma mistura que contém moléculas proteináceas, fração, e, usos de uma fração ou composição, e de eritropoietina recombinantemente produzìvel em uma célula de mamìfero
CN1374525A (zh) * 2001-12-31 2002-10-16 陕西超英生物医学研究开发有限公司 一种抗体芯片、其制备技术及其检测方法
AU2004226353A1 (en) 2003-04-01 2004-10-14 Laboratoires Serono Sa Inhibitors of phosphodiesterases in infertility
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
EP1654353B1 (en) * 2003-08-18 2013-05-22 Glycotope GmbH Tumour cell lines nm-f9 (dsm acc2606) and nm-d4 (dsm acc2605), uses threreof
DK1711834T3 (da) 2004-02-04 2010-11-29 Centre Nat Rech Scient Fremgangsmåde til screening af glycoform-specifikke antistoffer
US8609370B2 (en) * 2004-02-13 2013-12-17 Glycotope Gmbh Highly active glycoproteins-process conditions and an efficient method for their production
US20100062973A1 (en) * 2005-03-11 2010-03-11 Fresenius Kabi Deutschland Gmbh Production of bioactive glycoproteins from inactive starting material
US20070033927A1 (en) * 2005-08-15 2007-02-15 Homby Michael J Automotive diesel exhaust HC dosing valve
RU2309411C2 (ru) * 2005-11-24 2007-10-27 Ростовский НИИ акушерства и педиатрии МЗ РФ Способ отбора пациенток с синдромом "пустых" фолликулов для проведения программы эко и пэ донорскими ооцитами
KR100809945B1 (ko) * 2006-02-01 2008-03-05 대한민국 인체장내정상세균총 특이반응 dna칩 및 이를 이용한인체장내정상세균총의 변화에 의한 인체 위해성의 평가방법
JP2009544327A (ja) * 2006-07-21 2009-12-17 ノヴォ ノルディスク アー/エス O−結合型グリコシル化配列によるペプチドのグリコシル化
EP2054521A4 (en) * 2006-10-03 2012-12-19 Novo Nordisk As METHODS OF PURIFYING CONJUGATES OF POLYPEPTIDES
TWI488640B (zh) * 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI604850B (zh) 2009-10-05 2017-11-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2691119B1 (en) * 2011-03-31 2018-08-01 Ferring B.V. Pharmaceutical preparation
JO3092B1 (ar) * 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض

Also Published As

Publication number Publication date
US20200247863A1 (en) 2020-08-06
US20140249082A1 (en) 2014-09-04
AR125991A2 (es) 2023-08-30
AU2010304922A1 (en) 2012-03-29
KR101804479B1 (ko) 2017-12-05
RU2016118236A (ru) 2018-10-29
JOP20200039A1 (ar) 2022-10-30
US9676835B2 (en) 2017-06-13
CA2776790A1 (en) 2011-04-14
JP2018076296A (ja) 2018-05-17
BR112012007990A2 (pt) 2017-07-25
US20220340634A1 (en) 2022-10-27
LT2486051T (lt) 2020-07-10
RS60413B1 (sr) 2020-07-31
JP7292153B2 (ja) 2023-06-16
RU2016118236A3 (es) 2019-09-18
JP6176924B2 (ja) 2017-08-09
MX2012003951A (es) 2012-05-29
JP2023075144A (ja) 2023-05-30
TW201113030A (en) 2011-04-16
KR20190067256A (ko) 2019-06-14
IL250733A0 (en) 2017-04-30
TW201632198A (zh) 2016-09-16
JP6580104B2 (ja) 2019-09-25
IL218548A (en) 2017-03-30
RU2012112907A (ru) 2013-11-10
HRP20200941T1 (hr) 2020-09-18
AU2010304922B2 (en) 2014-11-06
JP6310440B2 (ja) 2018-04-11
PL2486051T3 (pl) 2020-09-07
TWI532495B (zh) 2016-05-11
KR20210141771A (ko) 2021-11-23
US10526390B2 (en) 2020-01-07
IL250733B (en) 2019-07-31
US11292824B2 (en) 2022-04-05
JP2020000246A (ja) 2020-01-09
HUE050793T2 (hu) 2021-01-28
ES2798258T3 (es) 2020-12-10
JP7196244B2 (ja) 2022-12-26
JP2016074680A (ja) 2016-05-12
KR20210014767A (ko) 2021-02-09
PT2486051T (pt) 2020-06-17
CN102549011A (zh) 2012-07-04
KR101987982B1 (ko) 2019-06-11
CN107050434A (zh) 2017-08-18
JP2013506708A (ja) 2013-02-28
KR102489143B1 (ko) 2023-01-13
RU2588650C2 (ru) 2016-07-10
CN107050434B (zh) 2021-07-27
US20130023476A1 (en) 2013-01-24
KR102213154B1 (ko) 2021-02-05
KR20190028823A (ko) 2019-03-19
KR20230012104A (ko) 2023-01-25
SI2486051T1 (sl) 2020-08-31
KR20170133531A (ko) 2017-12-05
EP2486051A1 (en) 2012-08-15
IL267556A (en) 2019-08-29
JP2021176867A (ja) 2021-11-11
EP3611185A1 (en) 2020-02-19
WO2011042688A1 (en) 2011-04-14
AR079876A1 (es) 2012-02-29
US8975226B2 (en) 2015-03-10
DK2486051T3 (da) 2020-06-22
RU2724528C2 (ru) 2020-06-23
KR20120094909A (ko) 2012-08-27
TWI604850B (zh) 2017-11-11
IL218548A0 (en) 2012-05-31
EP2486051B1 (en) 2020-03-25
US20180030107A1 (en) 2018-02-01

Similar Documents

Publication Publication Date Title
JOP20200039A1 (ar) مُستحضر صيدلي يشتمل على hcg مأشوب
EP4302783A3 (en) Modified relaxin polypeptides and their uses
MX348622B (es) Fsh recombinante que inlcuye alfa 2,3- y alfa 2,6-sialilacion.
IN2012DN06714A (es)
IN2011KN03851A (es)
UA103774C2 (uk) Модифіковані поліпептиди бичачого гранулоцитарного колонієстимулювального фактора (g-csf) та їх застосування
AU334234S (en) Clamp for fence panels
IN2012DN04748A (es)
IN2012DN04414A (es)
JO3755B1 (ar) تركيبات تستوستيرون
MX2012006980A (es) Polipeptidos de somatotropina porcina modificados y sus usos.
MX349301B (es) Polipéptidos de somatotropina bovina modificados y sus usos.
IN2011KN03928A (es)
MY168248A (en) Next-instruction-type field
IN2012DN04412A (es)
JO3497B1 (ar) مستحضر صيدلي يشتمل على hcg مأشوب
GB2491544A (en) Perpetum mobile
IN2012DN04805A (es)
UA42262U (en) 3-METHYL-7-β-HYDROXY-γ-(N-CHLOROPHENOXY)PROPYL-8-METHYLTHIOXANTINE EXHIBITING DIURETIC ACTION
AU313101S (en) Glass balustrading clamp - Frameless
UA35660U (en) Use of antihomotoxic preparations as cytoprotectors
CL2009001949S1 (es) Cajero automatico.
AU333244S (en) Control panel
AU325379S (en) Scarves
UA34276U (ru) 7-β-ГИДРОКСИЭТИЛ-3-МЕТИЛ-8-N-ПИРРОЛИДИНОКСАНТИН, КОТОРЫЙ ПРОЯВЛЯЕТ ДИУРЕТИЧЕСКОЕ ДЕЙСТВИЕ